|
1.
|
|
13 p, 409.0 KB |
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis
/
Worm, Margitta ;
Simpson, Eric L. (Oregon Health & Science University, Portland) ;
Thaçi, Diamant (University of Lübeck, Germany) ;
Bissonnette, Robert (Innovaderm Research (Montreal, Canadà)) ;
Lacour, Jean Philippe (Nice University Hospital (Niça, França)) ;
Beissert, Stefan (Technische Universität Dresden, Germany) ;
Kawashima, Makoto (Tokyo Women's Medical University, School of Medicine, Tokyo, Japan) ;
Ferrándiz, Carlos (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Smith, Catherine H. (King's College London) ;
Beck, Lisa (University of Rochester Medical Center, New York) ;
Chan, Kuo-Chen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Chen, Zhen (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Akinlade, Bolanle (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Hultsch, Thomas (Sanofi Genzyme, Cambridge, Massachusetts) ;
Staudinger, Heribert (Sanofi, Bridgewater, New Jersey) ;
Gadkari, Abhijit (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Eckert, Laurent (Sanofi, Chilly-Mazarin, France) ;
Davis, John D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Rajadhyaksha, Manoj (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Graham, Neil M. H. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Pirozzi, Gianluca (Sanofi, Bridgewater, New Jersey) ;
Stahl, Neil (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Yancopoulos, George D. (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Ardeleanu, Marius (Regeneron Pharmaceuticals, Inc, Tarrytown, New York) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. [...]
2019 -  10.1001/jamadermatol.2019.3617
JAMA Dermatology, Vol. 156 (december 2019) , p. 131-143
|
|
|
2.
|
|
9 p, 713.2 KB |
Efficacy of Dupilumab in Atopic Dermatitis : The Patient's Perspective
/
de Bruin-Weller, Marjolein (University Medical Center Utrecht) ;
Merola, Joseph F. (Harvard Medical School) ;
Hong, Chih-ho (Probity Medical Research) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Ettler, Karel (University Hospital Hradec Kralove (República Txeca)) ;
Sierka, Debra (Sanofi Genzyme, Cambridge) ;
Delevry, Dimittri (Regeneron Pharmaceuticals. Inc) ;
Chen, Zhen (Regeneron Pharmaceuticals. Inc) ;
Rossi, Ana Beatris (Sanofi Genzyme, Cambridge) ;
Universitat Autònoma de Barcelona
Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2-5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). [...]
2021 - 10.1007/s13555-021-00621-w
Dermatology and Therapy, Vol. 11 (november 2021) , p. 2123-2131
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
